|1.||Fang, Fang: 11 articles (10/2011 - 04/2006)|
|2.||Moss, Ronald B: 5 articles (06/2013 - 01/2009)|
|3.||Aschenbrenner, Laura M: 5 articles (08/2011 - 04/2006)|
|4.||Larson, Jeffrey L: 5 articles (08/2011 - 01/2009)|
|5.||Hedlund, Maria: 5 articles (08/2011 - 01/2009)|
|6.||Gubareva, Larisa V: 4 articles (08/2014 - 04/2006)|
|7.||Nicholls, John M: 4 articles (06/2013 - 01/2009)|
|8.||Mishin, Vasiliy P: 3 articles (08/2014 - 04/2006)|
|9.||Triana-Baltzer, Gallen B: 3 articles (02/2010 - 01/2009)|
|10.||Chan, Renee W Y: 3 articles (02/2010 - 01/2009)|
|2.||Influenza in Birds (Avian Flu)
11/15/2007 - "Here, we use a mouse model to evaluate the efficacy of DAS181 treatment against a highly pathogenic avian influenza H5N1 virus. "
09/01/2009 - "DAS181 treatment also effectively protects human lung tissue and pneumocytes against the highly pathogenic avian influenza virus H5N1 (A/Vietnam/3046/2004). "
09/01/2009 - "DAS181 and its analogues have previously been shown to be potently active against multiple strains of seasonal and avian influenza virus strains in several experimental models, including cell lines, mice, and ferrets. "
01/01/2009 - "DAS181 (Fludase), a sialidase fusion protein, has been shown to have inhibitory activity against a large number of seasonal influenza strains and a highly pathogenic avian influenza (HPAI) strain (H5N1). "
01/01/2009 - "DAS181 (Fludase) is a sialidase fusion protein in early clinical development with in vitro and in vivo preclinical activity against a variety of seasonal influenza strains and highly pathogenic avian influenza strains (A/H5N1). "
12/15/2012 - "Expanding the armamentarium against respiratory viral infections: DAS181."
10/01/2011 - "DAS181 should be systematically evaluated for severe PIV infection."
07/15/2010 - "Intranasal DAS181 in cotton rats, a model for human disease, significantly curtailed infection. "
09/01/2009 - "Two doses of DAS181 treatment given 12 h apart were sufficient to block H5N1 infection in the ex vivo lung tissue culture. "
09/01/2009 - "DAS181 inhibits H5N1 influenza virus infection of human lung tissues."
|4.||Human Influenza (Influenza)
11/01/2015 - "Treatment of influenza for three days with DAS181 reduced viral shedding. "
08/01/2014 - "The results warrant further investigation of DAS181 for influenza treatment. "
12/15/2012 - "DAS181 significantly reduced viral load in participants infected with influenza, thus warranting future clinical development of this novel host-directed therapy. "
12/15/2012 - "DAS181, a novel host-directed antiviral in development for influenza treatment, was assessed in this phase II clinical trial. "
01/01/2009 - "DAS181 treatment also protected mice from pandemic influenza A(H1N1)-induced pathogenesis. "
|5.||Paramyxoviridae Infections (Parainfluenza)
11/01/2013 - "Inhibition of primary clinical isolates of human parainfluenza virus by DAS181 in cell culture and in a cotton rat model."
06/01/2015 - "Successful Treatment of Parainfluenza Virus Respiratory Tract Infection With DAS181 in 4 Immunocompromised Children."
02/01/2014 - "We report the first 2 cases, to our knowledge, of successful DAS181 use in ventilated HSCT patients with severe parainfluenza lung disease. "
02/01/2014 - "DAS181 is a novel antiviral agent with activity against influenza and parainfluenza. "
11/01/2013 - "DAS181 is a novel drug in development for the treatment of influenza as well as human parainfluenza viruses (hPIVs). "
|2.||N-Acetylneuraminic Acid (Sialic Acid)
|4.||sialic acid receptor
|7.||Antiviral Agents (Antivirals)
|2.||Transplantation (Transplant Recipients)
|3.||Stem Cell Transplantation
|4.||Artificial Respiration (Mechanical Ventilation)